Outset Medical (OM)
(Delayed Data from NSDQ)
$3.73 USD
+0.19 (5.37%)
Updated May 31, 2024 04:00 PM ET
After-Market: $3.73 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
OM 3.73 +0.19(5.37%)
Will OM be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for OM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OM
Outset Medical, Inc. (OM) Reports Q1 Loss, Misses Revenue Estimates
Outset Medical (OM) Inks Multi-Year Deal to Boost Home Dialysis
OM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Inspire (INSP) Surges 9.9%: Is This an Indication of Further Gains?
Outset Medical, Inc. (OM) Expected to Beat Earnings Estimates: Should You Buy?
BD (BDX) Gears Up for Q4 Earnings: What's in the Offing?
Other News for OM
Outset Medical: Expecting Accelerated Growth And Reduced Cash Burn Going Forward
Novo weight loss therapy cuts mortality risk in kidney disease
Bank of America Securities Remains a Sell on Outset Medical (OM)
Analysts’ Top Healthcare Picks: Outset Medical (OM), Cytokinetics (CYTK)
U.S. dialysis volumes expected to rebound in 2024 despite GLP-1 impact